Silo Pharma Inc., a developmental stage biopharmaceutical company, has successfully closed a public offering, raising approximately $2 million. The offering involved 3,333,338 shares of common stock, along with series A-1 and series A-2 warrants, each allowing the purchase of up to 3,333,338 additional shares at an exercise price of $0.60 per share. The Series A-1 Warrants are exercisable immediately and expire in five years, while the Series A-2 Warrants also become exercisable immediately but expire in eighteen months. The funds raised will be used for general working capital. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。